bexarotene has been researched along with thyroxine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Corssmit, EP; Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP | 1 |
| Assaf, C; Bagot, M; Dummer, R; Duvic, M; Gniadecki, R; Knobler, R; Ranki, A; Schwandt, P; Whittaker, S | 1 |
| Golden, WM; Haugen, BR; Hernandez, TL; Sherman, SI; Weber, KB; Woodmansee, WW | 1 |
| Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP; Visser, TJ | 1 |
| Ranki, A | 1 |
| Abbott, L; Farah, R; Gopaluni, S; Hutchison, R; Perzova, R; Poiesz, BJ; Shrimpton, A | 1 |
| Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS | 1 |
| Appetecchia, M; Baldelli, R; Barnabei, A; Corsello, SM; Paragliola, R; Torino, F | 1 |
| Garcia Morillo, JS; Muñiz Grijalvo, O; Pamies Andreu, E; Rodriguez Suarez, S | 1 |
| Emoto, M; Hayashi, D; Imanishi, Y; Inaba, M; Kurajoh, M; Miyaoka, D; Morita, A; Nagata, Y; Tateishi, C; Toi, N; Tsuruta, D; Yamada, S | 1 |
| Cayrol, F; Cerchietti, L; Cremaschi, GA; Debernardi, M; Díaz Flaqué, MC; Magro, C; Marullo, R; Mulvey, E; Paulazo, A; Phillip, JM; Revuelta, MV; Ruan, J; Sterle, H; Zamponi, N | 1 |
4 review(s) available for bexarotene and thyroxine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Topics: Anticarcinogenic Agents; Bexarotene; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2006 |
CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Topics: Antineoplastic Agents; Azetidines; Bexarotene; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Contraindications; Exanthema; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Incidental Findings; Kidney Neoplasms; Male; Middle Aged; Mycosis Fungoides; Neoplasms, Multiple Primary; Simvastatin; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2008 |
Thyroid dysfunction as an unintended side effect of anticancer drugs.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bexarotene; Diphtheria Toxin; Humans; Hypothyroidism; Interferon-alpha; Interleukin-2; Lenalidomide; Neoplasms; Recombinant Fusion Proteins; Tetrahydronaphthalenes; Thalidomide; Thyroid Diseases; Thyroid Gland; Thyroid Hormones; Thyroxine | 2013 |
3 trial(s) available for bexarotene and thyroxine
| Article | Year |
|---|---|
Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.
Topics: Adult; Aged; Bexarotene; Carcinoma, Papillary; Cell Differentiation; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Retinoid X Receptors; Tetrahydronaphthalenes; Thyroid Neoplasms; Thyroidectomy; Thyrotropin; Thyroxine; Triiodothyronine | 2006 |
Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects.
Topics: Adult; Antineoplastic Agents; Bexarotene; Double-Blind Method; Fatty Acids, Nonesterified; Female; Humans; Male; Middle Aged; Tetrahydronaphthalenes; Thyrotropin; Thyroxine; Triglycerides; Triiodothyronine | 2007 |
Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones.
Topics: Aged; Anticarcinogenic Agents; Bexarotene; Drug Evaluation, Preclinical; Female; Humans; Hypothyroidism; Lung Neoplasms; Male; Middle Aged; Retinoid X Receptors; Tetrahydronaphthalenes; Thyroid Hormones; Thyroid Neoplasms; Thyrotropin; Thyroxine; Triiodothyronine | 2007 |
5 other study(ies) available for bexarotene and thyroxine
| Article | Year |
|---|---|
Bexarotene combination therapy for patients with Sézary syndrome.
Topics: Antineoplastic Agents; Atorvastatin; Bexarotene; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2008 |
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Topics: Adult; Amylases; Anticarcinogenic Agents; Bexarotene; Blood Cell Count; Blood Glucose; Cholesterol, HDL; Clinical Protocols; Drug Administration Schedule; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Liver Function Tests; Lymphoma, T-Cell, Cutaneous; Musculoskeletal Pain; Pancreatitis; Pregnancy; Pregnancy Complications; Skin Neoplasms; Tetrahydronaphthalenes; Thyrotropin; Thyroxine | 2013 |
[Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cholesterol, HDL; Combined Modality Therapy; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Male; Middle Aged; Mycosis Fungoides; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Salvage Therapy; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2016 |
Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients.
Topics: Bexarotene; Humans; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Retrospective Studies; Skin Neoplasms; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine | 2022 |
Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Humans; Integrin alphaVbeta3; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2022 |